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Abstract  SA Fam Pract 2009;51(6):486-488
Background: Depo Provera (medroxyprogesterone acetate) 150 mg intramuscular injection every 12 weeks is one of the most common, effective, 
affordable and popular methods of contraception. Depo Provera shows excellent results in comparison to oral contraceptive agents as well as the 
contraceptive patch.
Objective: The aim of the study was to determine the effects of the chronic use of medroxyprogesterone acetate 150 mg injections on the endometrium 
and myometrium of the uterus as measured by means of ultrasound.
Methods: An analytical case-control investigation was performed. Two groups were included and participants were actively selected and recruited 
by the researcher. Patients in both groups were similar with regard to socio-economic background, age and clinical profile. Each patient in the study 
group was paired with a patient in the control group. During patients’ visits, measurements were performed by means of a Medison Sonoace 5500 
digital ultrasound apparatus. A structured interview was conducted with each participant in order to obtain relevant patient information.
Results: Fifty participants were recruited and selected for both the study group and the control group. All the participants were women from 
the Thaba Nchu and Botshabelo municipal areas in the Free State Province, served by the researcher’s private general practice in Botshabelo. 
Participants in the study group (20–46 years; median age 31 years) were treated with Depo Provera, while the control participants (19–48 years; 
median age 30.5 years) were not on any chronic medication or hormonal contraception, did not have intrauterine devices and were not pregnant or 
breastfeeding during the 12 months preceding the study. The medians of all the parameters (uterus length and width; endometrial thickness) were 
determined in the patients selected from the researcher’s practice. The presence of uterine myomata was documented and compared between the 
two groups. Statistically significant differences with regard to all the measurements of the uterus and presence of myomata were observed between 
the study and the control group.
Conclusions: It was concluded that intramuscular administration of 150 mg medroxyprogesterone acetate was responsible for these differences.
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Introduction
Depo Provera (depot medroxyprogesterone acetate; DMPA) 150 mg 
intramuscular injection every 12 weeks is one of the most common 
methods of contraception used by the female population in Botshabelo, 
Free State Province.1 The endometrial thickness of the uterus is affected 
by Depo Provera to such an extent that it creates an unfavourable 
environment for implantation of a fertilised ovum, should ovulation 
occur. It is therefore regarded as one of the most effective contraceptive 
methods available. During the postpartum period it has some influence 
on lactation yet allows the mother to continue with breastfeeding. Depo 
Provera has the best Pearl Index value (i.e. 0–1) when compared to oral 
contraceptive agents or the contraceptive sticker (patch).2
This specific contraceptive method poses benefits as well as 
disadvantages.3 Currently some of the disadvantages of Depo Provera 
are actually utilised from a therapeutic perspective. Therefore, patients 
regularly present to the general practitioner with signs and symptoms 
related to side-effects of Depo Provera 150 mg injection.4
Depo Provera affects the endometrium and myometrium of the uterus.1 
Some of its side-effects, for example amenorrhoea, may be a cause of 
concern to some patients, while in others, for example women who suffer 
from endometriosis, it may have a therapeutic effect.5 Other side-effects 
of Depo Provera include acne, fluid retention, changes in weight and 
libido, depression, breast tenderness and breakthrough bleeding, which 
represent the most common reasons for seeking medical attention.6 
Breakthrough bleeding usually occurs during the first six months of using 
Depo Provera. A study in California reported that mifepristone (50 mg 
every second week for 24 weeks), a progesterone receptor antagonist, 
could be administered to limit breakthrough bleeding to a large extent.7
Ultrasound is used to measure endometrial thickness. It is a cost-effective, 
non-invasive procedure that is frequently used in the field of obstetrics 
and gynaecology.8,9 It does, however, require expertise, operator skill, 
training and experience to obtain accurate findings of clinical value.
In endometrial adenocarcinoma, ultrasound, in particular transvaginal 
ultrasound combined with MRI, is of great value in staging of the 
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specific case. Although most cases of endometrial adenocarcinoma 
occur in postmenopausal women, up to 25% of cases are reported in 
premenopausal patients. In selected cases, abdominal and transvaginal 
ultrasound is used to follow up on patients who have already received 
tumour regression therapy. When such patients do not want to fall 
pregnant, they can be placed on Depo Provera with periodic ultrasound 
evaluation to monitor endometrial thickness.10  Depo Provera has 
also been used with success for preoperative regression of uterine 
myomata.11
The aim of the study was to determine the effects of chronic use of Depo 
Provera 150 mg injection on the endo- and myometrium of the uterus by 
means of ultrasound.
Methods
An analytical case-control study was performed. All the participants were 
female patients from the Botshabelo and Thaba Nchu municipal areas 
in the Free State Province, who voluntarily visited the private general 
practice of the researcher in Botshabelo between October 2006 and 
May 2007. This practice renders services to approximately 2 500 patients 
per month, of whom 60% are female. Sixty-six Depo Provera 150 mg 
injections are administered each month. Active recruitment and selection 
of the participants was done by the researcher. Patients of similar socio-
economic background, age and clinical profile were selected for both the 
study and control groups. Participants in the study group were matched 
to participants in the control group by age (within two years).
The study group consisted of 50 women of reproductive age (20–46 
years) who had been on Depo Provera 150 mg for longer than 
12 months. Participants in the study group underwent a lower abdominal 
sonar investigation and received a Depo Provera 150 mg injection at the 
first visit. Both the investigation and the contraceptive injection were 
repeated 12 weeks later. Both visits were free of charge. Any local or 
systemic side-effects resulting from the Depo Provera injection or the 
lower abdominal sonar were managed free of charge.
Fifty women (19–48 years) who were not on any chronic medication 
or hormonal contraception, did not have intrauterine devices and were 
not pregnant or breastfeeding during the 12 months preceding the first 
ultrasound investigation were included in the control group. Participants 
in the control group underwent two lower abdominal sonar investigations 
12 weeks apart, free of charge. No Depo Provera was administered to 
the control group.
A structured interview was conducted with each participant during the 
consultation.
Uterine measurements were performed by means of a Medison Sonoace 
5500 digital ultrasound apparatus. Measurements included uterine length 
and width, endometrial thickness and the presence or absence of uterine 
myomata. The researcher, who had formal training in gynaecological 
ultrasound procedures, conducted all the measurements. No invasive 
procedures were performed as part of the study.
The size of the uterus was determined by taking two measurements, 
from both left and right lateral views, measuring the length of the uterus 
from the fundus to the internal os of the cervix and the largest diameter 
of the fundus from left to right. Measurements were annotated on a 
specially designed data sheet.
In the event of detecting any pathology during the ultrasound 
investigation, patients were either treated by the general practitioner 
(researcher) in his practice or referred for specialised evaluation and 
treatment if necessary.
Descriptive statistics, namely medians and percentiles for continuous 
data and frequencies and percentages for categorical data, were 
calculated for each group. The results for the two groups were compared 
by means of 95% confidence intervals for paired data.
A pilot study was performed using three patients to test the information 
leaflet, the questionnaire and the document designed to annotate the 
measurements. These patients’ findings were excluded from the study.
An information leaflet compiled in three languages (Afrikaans, English 
and Sesotho) was handed to each of the participants selected for 
the study. Since the researcher is fluent in all three these languages, 
information was also conveyed verbally to each participant in her 
language of choice.
Participation was voluntary and participants gave written informed 
consent to be included in the study. Refusal to participate was not 
penalised and patients who refused to participate continued to enjoy full 
benefits as clients of the private practice. All information was handled 
with confidentiality. Ethical approval to conduct the investigation was 
granted by the Ethics Committee of the Faculty of Health Sciences, 
University of the Free State (ETOVS number 169/06).
Results
The study group and the control group consisted of 50 participants each. 
All the participants were residing in either Thaba Nchu or Botshabelo 
in the Free State Province, both towns being included in the drainage 
area served by the researcher’s private general practice situated in 
Botshabelo. 
Only 46 of the participants could be matched by age. The median age of 
the participants was 31 years (range 19–46 years). 
Ninety-two per cent of the study group were Sesotho speaking, while the 
rest were English speaking. In the control group, 96% of the participants 
were Sesotho speaking and 2% were English speaking, while one (2%) 
participant was isiXhosa speaking.
The median number of years that the study group participants had 
been receiving Depo Provera 150 mg injection every 12 weeks as a 
contraceptive measure was four years (minimum one year; maximum 
13 years). As noted in the Methods section, none of the control group 
participants were on Depo Provera.
None of the participants in the control group reported amenorrhoea as 
opposed to 85% of the study group who reported amenorrhoea of at least 
six months duration preceding the study. The difference was statistically 
significant (95% CI [69.7%; 92.4%]).
Fifty-two per cent of participants in the study group reported 
breakthrough bleeding, while it was reported by only 8% of the control 
group. Breakthrough bleeding occurred significantly more in the study 
group with 95% CI [31.3%; 61.6%].
The medians of all the uterus measurements (length, width and 
endometrial thickness) were calculated. These findings are shown in 
Table I.
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Statistically significant differences between the study group and 
the control group were found with regard to uterus width on first 
measurement (95% CI [0.1; 0.2]) and endometrial thickness on first 
measurement (95% CI [0.1; 0.1]). The difference between the two groups 
with regard to uterus width on second measurement was not significant 
(95% CI [–0.4; 0.2]), endometrial thickness second measurement (95% 
CI [–0.1; 0.1]), uterus length on first measurement (95% CI [0; 0.2]) as 
well as second measurement (95% CI [–0.1; 0.3]).
Changes in uterus length and width as well as endometrial thickness 
from the first to the second measurement were documented for each 
participant and compared between the study group and the control 
group. Statistically significant differences were observed with regard 
to uterus width (95% CI [0.1; 0.6]). On the other hand, the difference 
between the two groups in changes in uterus length and endometrial 
thickness from the first to the second measurement was not significant 
(95% CI [–0.1; 0.2] and [0; 0.2] respectively).
In the study group, no uterine myomata were found in 96% of participants 
with the first ultrasound examination, while 4% of participants presented 
with a single myoma. These two patients had been on Depo Provera 
150 mg for three and 6.5 years, respectively. With the second ultrasound 
examination 12 weeks later, these findings remained unchanged. 
In comparison, 94% of control group participants were free from 
uterine myomata. Three (6%) of the control participants, however, had 
myomata on first examination, of which one patient presented with a 
single myoma and the other two with two myomata each. On second 
ultrasound examination, 92% of the control group did not have myomata, 
while three participants (6%) presented with a single myoma and one 
(2%) with two myomata. Statistically there was no significant difference 
between the two groups (95% CI [–14.5%; 4.0%]).
Discussion
Statistically significant differences between the study group and the 
control group were observed in some of the uterus measurements and 
endometrial thicknesses, which could be attributed to the intramuscular 
administration of medroxyprogesterone acetate 150 mg every 12 weeks. 
The measurements of the study group participants for uterine width and 
endometrial thickness were significantly lower than the measurements 
observed in the control group. These findings are supported by the 95% 
confidence interval for the median differences. It was determined that 
the use of Depo Provera caused chemical ablation of the endometrium.
The study group also presented with significantly more breakthrough 
bleeding than the control group, which led to the conclusion that Depo 
Provera was responsible for this observation. This finding is corroborated 
by the literature. Different options are available to limit this side-effect 
of medroxyprogesterone acetate, for example mefenamic acid 500 mg 
t.i.d., Ovral® therapy, mifepristone 50 mg every two weeks for 24 weeks 
(although this is an expensive option) or even intravenous Cyklokapron® 
(tranexamic acid) in severe, acute cases of breakthrough bleeding.
The incidence of uterine myomata in the study group was lower than 
in the control group, although no significant differences were observed. 
In retrospect, the 12-week period is, according to the literature, not a 
sufficient length of time to determine whether Depo Provera had any 
impact on the development or regression of uterine myomata.12 A larger 
study including more participants and conducted over a substantially 
longer period could shed more light on this matter.
The findings of this study confirm that Depo Provera may cause 
significant decrease in the volume of the uterus and in endometrial 
thickness, which may be of value in clinical practice when patients are 
treated with medroxyprogesterone acetate as contraceptive agent. 
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Table I: Uterus measurements in the study and control groups as 










Minimum (mm) 37.6 44.1 37.6 43.8
Median (mm) 54.7 60.6 56.4 60.6
Maximum (mm) 81.7 88.7 81.4 88.3
Uterus width
Minimum (mm) 21.4 24.8 21.2 24.6
Median (mm) 31.2 33.9 30.9 33.7
Maximum (mm) 44.9 47.6 44.7 47.1
Endometrial thickness
Minimum (mm) 0.2 0.8 0.2 1.0
Median (mm) 1.2 2.9 1.2 2.9
Maximum (mm) 2.7 3.7 2.6 3.7
